Aquestive Therapeutics, Inc. (NASDAQ:AQST) Short Interest Update

Aquestive Therapeutics, Inc. (NASDAQ:AQST) was the recipient of a significant growth in short interest in the month of January. As of January 15th, there was short interest totalling 10,480,000 shares, a growth of 8.6% from the December 31st total of 9,650,000 shares. Based on an average daily trading volume, of 1,550,000 shares, the short-interest ratio is presently 6.8 days.

Aquestive Therapeutics Price Performance

AQST traded down $0.13 on Monday, reaching $2.90. The company’s stock had a trading volume of 614,589 shares, compared to its average volume of 1,399,406. Aquestive Therapeutics has a 1 year low of $2.24 and a 1 year high of $6.23. The business’s 50 day moving average is $3.65 and its 200 day moving average is $4.22. The stock has a market cap of $263.97 million, a price-to-earnings ratio of -6.41 and a beta of 2.67.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Monday, November 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01). The company had revenue of $13.54 million for the quarter, compared to analyst estimates of $12.69 million. During the same period in the previous year, the business posted ($0.03) EPS. As a group, research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current fiscal year.

Analyst Ratings Changes

AQST has been the subject of several research reports. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a research note on Tuesday, December 17th. They set an “overweight” rating and a $17.00 price objective for the company. Leerink Partners raised their price objective on Aquestive Therapeutics from $12.00 to $13.00 and gave the company an “outperform” rating in a research report on Friday, October 25th. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 target price on shares of Aquestive Therapeutics in a research report on Tuesday, October 8th. Finally, HC Wainwright reiterated a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a report on Friday, December 20th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Aquestive Therapeutics presently has a consensus rating of “Buy” and a consensus target price of $11.00.

Hedge Funds Weigh In On Aquestive Therapeutics

Large investors have recently modified their holdings of the stock. Verition Fund Management LLC bought a new position in Aquestive Therapeutics during the 3rd quarter worth approximately $995,000. State Street Corp lifted its stake in Aquestive Therapeutics by 52.1% during the third quarter. State Street Corp now owns 1,496,739 shares of the company’s stock worth $7,454,000 after purchasing an additional 512,682 shares during the last quarter. Wellington Management Group LLP acquired a new position in Aquestive Therapeutics in the third quarter worth $922,000. Chartwell Investment Partners LLC bought a new stake in Aquestive Therapeutics during the third quarter valued at $535,000. Finally, BNP Paribas Financial Markets raised its holdings in shares of Aquestive Therapeutics by 252.2% during the third quarter. BNP Paribas Financial Markets now owns 18,826 shares of the company’s stock worth $94,000 after purchasing an additional 13,481 shares during the period. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.